Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nithya Ramnath"'
Autor:
Lyudmyla Derby, Mary E. Reid, Raj Natarajan, Gerald J. Fetterly, Sikander Ailawadhi, Nithya Ramnath
Publikováno v:
Oncology. 76:85-90
Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice. Methods:
Autor:
J. Alkhaddo, G. Loewen, F. Eid, Ravi Menezes, Mary E. Reid, Nithya Ramnath, Nachimuthu Natarajan, P. Dua, G. Paganelli
Publikováno v:
Oncology. 73:305-310
Purpose: It was the aim of this study to assess the risk of lung cancer in postmenopausal women who received hormone replacement therapy (HRT). Experimental Design: This case-control study involves women who received medical services at Roswell Park
Publikováno v:
Oncology. 85(4)
Background: Chemotherapy-associated neutropenia has been reported to be a pharmacodynamic marker of response in some advanced solid tumors. Factors that accelerate drug clearance lead to lower plasma concentrations and toxicity, including neutropenia
Autor:
Sikander, Ailawadhi, Lyudmyla, Derby, Raj, Natarajan, Gerald, Fetterly, Mary, Reid, Nithya, Ramnath
Publikováno v:
Oncology. 76(2)
Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice.We retrospectively an
Autor:
Nithya Ramnath, Peter Kanter, S.G. Eckhardt, Ralph J. Bernacki, C. Lathia, G. Schwartz, J. Hamm, Michael R. Vredenburg, Patrick J. Creaven, S. Holden
Publikováno v:
Oncology. 67(2)
Purpose: To determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the pharmacokinetics of BAY59, a novel taxane given as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory solid tumors. Exper